Reações infusionais imediatas a agentes imunobiológicos endovenosos no tratamento de doenças autoimunes: experiência de 2.126 procedimentos em um centro de infusão não oncológico

Moraes, 2010, Complicações imediatas de 3.555 aplicações de agentes anti-TNFα, Rev Bras Reumatol., 50, 165, 10.1590/S0482-50042010000200006 Chung, 2008, Managing premedications and the risk for reactions to infusional monoclonal antibody therapy, Oncologist., 13, 725, 10.1634/theoncologist.2008-0012 Heinz, 2007, Management and preparedness for infusion and hypersensitivity reactions, Oncologist., 12, 601, 10.1634/theoncologist.12-5-601 Remicade. [Bula]. Malvern: Centocor Inc.; 2006. Actemra. [Bula]. San Francisco: Genentech Inc.; 2011. Rituxan. [Bula]. South San Francisco: Genentech Inc.; 2006. Orencia. [Bula]. Princeton: Bristol-Myers Squibb; 2008. National Institutes of Health National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.02: Sep 2009. Avaliable from ftp://ftp1.nci.nih.gov/pub/cacore/EVS/CTCAE/Archive/CTCAE_4.02_2009-09-15_ QuickReference_8.5x11.pdf. Vogel, 2010, Infusion reactions: diagnosis assessment management, Clin J. Oncol Nurs, 14, E10, 10.1188/10.CJON.E10-E21 Dillman, 2003, Unique aspects of supportive care using monoclonal antibodies in cancer treatment, Support Cancer Ther., 1, 38, 10.3816/SCT.2003.n.003 Breslin, 2007, Cytokine-release syndrome: overview nursing implications, Clin J. Oncol Nurs, 11, 37, 10.1188/07.CJON.S1.37-42 Kang, 2007, Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer – Identification, prevention, and management, J Support Oncol., 5, 451 Kimby, 2005, (MabThera). Tolerability and safety of rituximab, Cancer Treat. Rev, 31, 456, 10.1016/j.ctrv.2005.05.007 Zanotti, 2001, Prevention and management of antineoplastic induced hypersensitivity reactions, Drug Saf., 24, 767, 10.2165/00002018-200124100-00005 Dillman, 1999, Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy, Cancer Metastasis Rev., 18, 465, 10.1023/A:1006341717398 Du Pan, 2009, Finckh. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis, Arthritis Rheum, 61, 560, 10.1002/art.24463 Kapetanovic, 2006, Geborek P. Predictors of infusion reactions during infliximab treatment in patients with arthritis, Arthritis Res Ther., 8, R131, 10.1186/ar2020 Botsios, 2005, Incidence and management of infusion reactions to infliximab in 186 italian patients with rheumatoid arthritis: the Padua experience, Reumatismo, 57, 44 Baeten, 2003, Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defense in the pathogenesis of the disease?, Ann Rheum Dis., 62, 829, 10.1136/ard.62.9.829 Barbaud, 2011, How to manage hypersensitivity reactions to biological agents?, Eur J. Dermatol, 21, 667, 10.1684/ejd.2011.1468 Shergy, 2002, Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis, J Rheumatol., 29, 667 Cheifetz, 2003, The incidence and management of infusion reactions to infliximab: a large center experience, Am J Gastroenterol., 98, 1315, 10.1111/j.1572-0241.2003.07457.x Thaler, 2012 Hanauer, 2002, Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial, Lancet, 359, 1541, 10.1016/S0140-6736(02)08512-4 Augustsson, 2007, Low-dose glucocorticoid therapy decreases risk for treatment limiting infusion reaction to infliximab in patients with rheumatoid arthritis, Ann Rheum Dis., 66, 1462, 10.1136/ard.2007.070771 Hong, 2012, Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies, Expert Rev Clin Immunol., 8, 43, 10.1586/eci.11.75 Wasserman, 2004, Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number, J Rheumatol., 31, 1912 Tanaka, 2010, Tocilizumab for the treatment of rheumatoid arthritis, Expert Rev Clin Immunol., 6, 843, 10.1586/eci.10.70 Nishimoto, 2007, Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (Samurai): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab, Ann Rheum Dis., 66, 1162, 10.1136/ard.2006.068064 Davis, 1999, Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab, J Clin Oncol., 17, 1851, 10.1200/JCO.1999.17.6.1851 Davis, 2000, Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment, J Clin Oncol., 18, 3135, 10.1200/JCO.2000.18.17.3135 Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed lowgrade non-Hodgkin's lymphoma. Blood. 199;90:2188-2195. Plosker, 2003, a review of its use in non- Hodgkin's lymphoma and chronic lymphocytic leukemia, Drugs., 63, 803, 10.2165/00003495-200363080-00005 Tony, 2011, Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID), Arthritis Res Ther., 13, R75, 10.1186/ar3337 Kremer, 2005, Treatment of rheumatoid arthritis with the selective. costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial, Arthritis Rheum, 52, 2263, 10.1002/art.21201 Schiff, 2009, The 6-month safety and effi y of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial, Ann Rheum Dis., 68, 1708, 10.1136/ard.2008.099218 Ruperto, 2008, Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial, Lancet, 372, 383, 10.1016/S0140-6736(08)60998-8 Singh, 2011, Adverse effects of biologics: a network metaanalysis and Cochrane overview, Cochrane Database Syst Rev, 2, CD008794 Weinblatt, 2006, Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one- year randomized, placebo-controlled study, Arthritis Rheum, 54, 2807, 10.1002/art.22070